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ABSTRACT
DNA-protein interaction studies in vitro revealed sev-
eral factors binding over the TATA box and the region of
transcription initiation (cap) site of the human f-globin
promoter; TATA binding protein TBP at -30, Spl at -19,
GATA-1 at -12 and +5, YY1 at -9 and a novel factor Cl
over the site of initiation (-4 to +7). Point mutants which
specifically abolish the binding of each of these
proteins were tested in a -globin locus control region
(LCR) construct which allows quantitative comparisons
at physiological levels of transcription. Only mutants
which drastically affect the binding of TBP resulted in
decreased levels of transcription. A threshold value of
TBP binding of 15-30% of wild type was sufficient to
give normal levels of transcription. This indicates that
the association of TF IID with the TATA box is not
limiting in the rate of initiation of transcription.
INTRODUCTION
The initiation of transcription by RNA polymerase II (Pol II) in
TATA box containing promoters is currently thought to be
dependent on the efficiency of binding of the TF HD complex to
the promoter. The binding of TF IID at the promoter initiates a
sequential interaction of the basic transcription factors TF IIA, B,
E, F, G, H andRNA Pol II with the template to form the initiation
complex (for review see ref. 1).
Although initially discovered as a large, multi-component
complex (>700 kDa; 2,3) that would bind at the TATA element
at-30 ofmany class II genes, TF IID is now known to be involved
in transcription from promoters that lack a canonical TATA box
(4,5). In this latter situation, other factors binding at the promoter
are envisaged to act, at least in part, in a 'tethering' capacity
helping to anchor TF IID to the template. From the study of such
class II promoters, a second element involved in initiation of
transcription was discovered, namely, the 'initiator' (Inr) which
is usually located over the transcriptional start or cap site (6). In
addition to the TATA box, different Inr elements have been
identified for different promoters (7).
The TATA binding protein (TBP) component of TF IID has
been cloned and characterized from many different species (8)
and has since been shown to be a 'core' component of the
initiation complex of Pol I and Pol Ill promoters where it forms
part of the SLI and TF IIIB/SNAPc factors, respectively (9,10
and refs therein). A different set of TBP associated factors
(TAFs), allows it to function as a nucleation centre for the basic
transcriptional machinery on the promoters of all classes of genes
(11). TAFs which mediate both activation and repression of
transcription have been described (12,13).
Studies in vitro suggest that the rate of association of TF IID
with the promoter is slow and therefore thought to be rate limiting
in the formation of the pre-initiation complex (14,15). However,
it is not clear that this is the case in vivo. Transient transfection
assays have suggested that TF ID may be rate limiting on
TATA-containing but not TATA-lacking promoters (16). The
main problem associated with such studies is that they do not
study the initiation of transcription at the same level as normally
occurs in vivo in a natural chromatin environment and in the
context of all the regulatory sequences for a given gene. However,
the discovery of the key regulatory elements in the human
P-globin gene locus has made such an analysis possible.
The high level erytbroid and developmental stage-specific
expression of the ,-like globin genes is under the primary control
of the locus control region (LCR) which is located 5' of the entire
gene cluster. The ,B-globin LCR consists of five developmentally
stable, erythroid-specific regions of DNaseI hypersensitivity
(17-19; Raguz and Grosveld, in preparation) and is defined by its
ability to confer physiological levels of expression of the globin
genes independent of the position of integration in the host genome
of transgenic mice (17) and stable transfected erythroid tissue
culture cells (20,21).
In earlier studies we have shown that the PLCR can fully
activate transcription from a minimal (-globin promoter consist-
ing of a TATA box (-30), CCAAT (-75) and CACC (-90)
elements (22). These results indicated that erythroid specific
transcription by the [LCR was mediated through theCCAAT and
CACC regions, because deletion of these elements leads to the
loss of erythroid specific induction of transcription. In addition,
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there have been reports suggesting that factors binding at the
TATA box region of P-globin genes are also involved in
erythroid-specific transcription. In the mouse f-maj globin
promoter, a 10 bp direct repeat elementjust upstream ofthe TATA
box has been defined (23,24) and for the adult chicken ,-globin
gene, the TATA box region also binds the erythroid factor
GATA-1 (25).
Because of these results and to gain further insight into the
molecular mechanisms of LCR/promoter interactions, we under-
took a study to characterize the factors binding at the TATA box
and cap region ofthe human [B-globin gene and to assess their role
in transcription initiation in vivo. To achieve this, we used the
iLCR in stable transfected MEL cells to obtain quantitative
comparisons between different mutant promoters. Our data
clearly indicate that although experiments in vitro showed several
factors binding over this region, only TF IID is functional at the
TATA box in vivo. Mutants capable of strongly binding GATA-1
at this site, give rise to transcripts with aberrant start sites. The
results also suggest that upstream promoter binding factors may
play a more active role in positioning TF UD on a TATA-less
promoter than previously thought.
MATERIALS AND METHODS
DNA constructs
As before, the hybrid human ,B-globin/mouse H2K gene (22) was
used as the reporter system for the functional analysis of the
promoter mutants in these studies. This gene consists of the
[-globin promoter from the SnaBI site at-265 to aHindlm linkered
site at +30 from the start of transcription. This promoter is joined
to a HindLll linkered NruI site at +9 in exon I of the H2K gene. The
promoter region of this hybrid gene extending from the -265
SnaBI site to the NotI site at +85 within exon I was sub-cloned
between the HincH and NotI sites of pBluescript (Stratagene).
Unique SmaI and XbaI sites at -40 and +11, respectively, were
created by point mutagenesis within this sub-clone. All other
promoter mutants were constructed by the direct substitution ofthe
sequences between -40 and +11 by a series of overlapping
oligonucleotides containing the relevant mutation. All mutant
promoters were confirmed by sequence analysis. The wild-type
promoter of the -H2 hybrid gene in the microlocus LCR
expression vector (22), was replaced with these mutant elements
as ClaI-NotI fragments. The microlocus consists of all four
elements ofthe LCR as a 6.5 kb fragment which retains full activity
(21,26). All constructs were linearised at the PvuI site within the
ampicillin resistance gene of the vector prior to transfection into
MEL and L-cells (see below).
Electrophoretic mobility shift assays (EMSA)
Electrophoretic mobility shift assay analysis was carried out using
total nuclear protein extracts from HeLa, K562 and MEL cells as
described previously (27). Bacterially expressed TBP was pro-
vided by Steve Jackson (Cambridge, UK) and the TBP EMSAs
were quantitated by phosphorimage analysis, using a Molecular
Dynamics phosphorimager (Fig. 3). Methylation interference
Expression studies
The maintenance, transfection by electroporation and selection of
stable transfected pools of MEL cells was exactly as previously
described using 50 jg linearised plasmid DNA and 3 x 107 cells
per sample (28). Murine fibroblast L-cells were grown inDMEM
containing 10% (v/v) foetal calf serum. L-cells were transfected
with Lipofectin (Gibco-BRL) according to the manufacturer's
instructions, using 20 ,ug linearised plasmid DNA, 100 ,ug
lipofectin and 3 x 106 cells seeded on a 10 cm diameter Petri dish.
Stable transfected clones were selected in 500 ,ug/ml G418
(Gibco-BRL) and were obtained at a frequency of -I in 104.
The preparation of RNA and analysis by S 1-nuclease protec-
tion assays were carried out as before using 5' end-labelled DNA
probes (22,28).
In the case of the various mutations, homologous probes were
isolated for the analysis in order to measure aberrantly initiated
transcripts. The results were analysed by autoradiography and
quantitated by phosphorimage analysis. A 350 bp Clal-NotI
fragment from the 5' end of the [VH2K hybrid gene was used to
give a 85 nt SI-nuclease protected product (22). A 700 bp
HindIII-NcoI fragment from the 5' halfofthe mouse [-maj globin
gene was used which gives a 96 nt S 1-protected product from the
5' portion of the second exon of the mRNA (27). The ,3-actin
probe was a 320 bp BamHI-Aval fragment from a human ,3-actin
cDNA clone (29) which gives a 100 nt S 1-protected product from
the homologous murine mRNA (30). The products were resolved
on a 6% polyacrylamide gel in the presence of 8 M urea.
RESULTS
TATA box and Cap site binding factors
Initial in vitro DNaseI footprint experiments on the human
3-globin promoter using total nuclear extracts from erythroid
(murine erythroleukaemia, K562) and non-erythroid (HeLa)
cells, revealed an extended area of protection from the TATA box
to past the site of initiation of transcription (data not shown). To
gain insight into the factors binding over this region, EMSA were
employed using the same nuclear extracts and two overlapping
oligonucleotides from -34 to -I (TATA) and from -22 to +9 (Cap;
Fig. 1, Table 1). Both probes showed several retarded bands,
indicating that multiple proteins could potentially bind over the
TATA box (T1, T2 and T3) and cap site regions (C1, C2A, C2B
and C3). The bands between T2 and T3 or C2 and C3 as well as
those below T3, are non-specific as they do not self-compete. One
of these factors (T2/C2B) was detected only with the erythroid
extracts and was bound by both the TATA and Cap probes.
Another factor (T3/C3) that was not erythroid-specific, also
seemed to bind to both TATA and Cap oligonucleotides. A slow
migrating species was seen with both probes (TI and C1).
However, this did not appear to be the same protein, as it was not
cross competable by the two probes used (Fig. 2A). Sequence
comparison, migration characteristics and competition experi-
ments provided identification of most of these factors (Fig. 2A)
and the results are summarized in Table 2 (upper panel). The
factor T2/C2B is GATA-1 as it was competed efficiently by a
probe corresponding to the -200 GATA-I binding site from the
human ,B-globin promoter (27; Fig. 2A, lanes GATA) and could
be supershifted with GATA-I antibodies (31; data not shown).
The residual binding activity with the Cap probe after GATA
experiments were carried out as described previously (27). competition is the weakly binding factor C2A (Fig. 1) which has
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Table 1. Methylation interference and point mutants at the human P-globin
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The sequence of the normal (WT) promoter is shown on a white background
(inverse filled triangle represents initiating nucleotide). Above the sequence are
the methylation interference sites forthe C1, Spi, GATA-1 and YY1 complexes
(see Figs 1 and 2). In each grey bar the protected bases of the sense strand are
shown on top, the protected bases on the anti-sense strand on the bottom. The
TATA region protection is shown in black dots; the cap site protection is shown
in white. The cap site (+ 1) is at the second A from the right. Below the sequence
are the different oligonucleotides with the mutations indicated in the grey bars.
The length of each bar indicates the length of the oligonucleotide used in the
EMSAs in Figures 1 and 2.
a slightly slower mobility than GATA- 1 and is not affected by
GATA-1 antibodies (data not shown). The factor designated
T3/C3 was competed by an oligonucleotide corresponding to the
YYl binding site (32,33) from the cap region of the adeno-asso-
ciated virus p5 gene (Fig. 2A, lanes YY1). The protein TI appears
to be SpI as it is competed by the binding site for this factor from
the SV40 virus enhancer (Fig. 2A, lanes Spl) and the complex
can be supershifted with antibodies to SpI (data not shown). The
factors C I andC2A were not competable by any ofthe probes that
were tried, including that for the initiator element from the TdT
gene (data not shown). Methylation protection experiments
(summarized in Table 1) were used to determine the position of
the binding sites of each of the proteins. This showed that in
addition toTF IRD, the erythroid factor GATA-1 and SpI bindjust
downstream of the TATA box. The GATA binding region is a
non-consensus site corresponding to a GATGGC sequence
between -9 and -14 on the anti-sense strand (34). The protein
which appears to be YY1, which can act both as an initiator and
a transcriptional repressor (32,33) is also found at this position.
(Note that the YY1 oligonucleotide has a weak GATA-1 binding
activity which cross competes T2 and C2B.) Over the cap site,
three proteins are seen to bind, namely, GATA-1 and two
unidentified factors which are not eryftroid-specific and are
designated C1 and C2A (Fig. 1). This GATA-1 site again
corresponds to a non-consensus TAAG element between +1 and
-3 on the anti-sense strand (34). We did not detect any binding of
the well characterized initiator protein TF 1 1 (35). The binding
of TF IID was only detectable in high salt conditions in crude
extracts and was difficult to quantitate precisely (2,36 and data
not shown). We therefore used recombinant TBP as a measure of
ri-
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Figure 1. Protein factors binding to the TATA box and cap site regions of the
human P-globin promoter. Upper panel: nucleotide sequence of the human
f3-globin proximal promoter from -40 to +11 relative to the cap site (+1). The
extent of the two overlapping oligonucleotides used to assess protein factors
binding to this region in EMSAs (lower panel) are marked; -35 to -1 (TATA
probe) and -23 to +11 (Cap probe). These oligonucleotides are equivalent in
length to the mutants used in subsequent experiments (Table 1). Lower panel:
EMSAs employing the TATA and Cap probes described above (see Materials
and Methods). The nuclear extracts used were from the following cell types:
murine erythroleukaemia (MEL) both before (-) and after (+) 2 days ofinduced
erytiroid differentiation; human myelogenous leukaemia K562; HeLa. The
extract used in a given assay is indicated at the top of each lane. The various
complexes formed with the TATA probe (T1-T3) and Cap probe (Ci-C3) are
marked.
TF IID binding at the TATA box under the low salt conditions
used in all the other EMSA experiments (see below).
Information from methylation interference data was used to
generate mutations for each of the proteins. These mutants are
summarized in Table 1 and we used EMSA to show that the
mutations specifically abolish the binding of each of the factors
without creating any new activity (Fig. 2B), mTl for Spl, mT2
andmT2A for GATA-1 and mT3 for YY1. Of these mutants mT3
also showed a reduced binding for the TATA box factor TBP (Fig.
3) although we currently have no explanation for this observation.
In addition to mT3, we generated a further set of TATA mutants
which show a decreasing capacity to bind TBP (Fig. 3, Table 2),
namely mT10 and mT7 which bind -4% and <4% respectively,
mT5 (13%), mT6 (30%) and mT9 (50%).
The mutants for each ofthe factors were subsequently built into
a ,-globin promoter extending to the SnaBI site at -265. To
facilitate cloning of the mutant oligonucleotides, the promoter
was first modified by point mutations at -40 and +11 to create
SmaI and XbaI sites, respectively (see Materials and Methods).
The introduction of these mutations does not affect the transcrip-
tion of the promoter (data not shown). Each of the mutant
promoters, in turn, was incorporated into the microlocus LCR
k irA I A 1:
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Figure 2. Identification of factors binding at the TATA box and cap site region
of the human f3-globin gene. (A) EMSAs in the presence of various competitor
or mutated oligonucleotides were performed to gain insight into the identity of
the factors binding to the TATA and Cap site probes. The TATA and Cap probes
(0.2 ng) described in Figure 1 were used in a series of EMSA in the presence
of 100-fold excess (50 ng) of unlabelled competitor oligonucleotide which
specifically binds the following factors: transcription factor Spl, erythroid
factor GATA-1 and initiator protein YY1. Reactions were also self and cross
competed with TATA or Cap probes. Assays in the absence of competitor are
also shown. (B) Analysis of the mutant TATA box and cap site oligonucleotides
(Table 1). Note that the Twt oligonucleotide in the middle panel is shorter (-38
to -11) than that used in (A) or the left hand panel of this figure (-34 to -1) and
tenninates atthe same position as T6, T8, T9 and TlO (Table 1). Complexes T1,
T2 and T3 are therefore absent in these assays. The nuclear extract used in all
cases was from uninduced MEL cells. The complexes marked are the same as
in Figure 1.
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Figure 3. Assessing TATA box mutants for binding of TBP. The TATA box
mutants listed in Table 1 were assessed by EMSAs for their ability to bind
recombinant TATA binding protein (TBP). The oligonucleotide probes (0.2 ng)
used were the same as those described in Figure 2. The wild type (Twt) sequence
acted as a control. This figure shows the phosphorimage which was used to
quantify the data (Table 2). The result with the wild type human f,Bglobin TATA
box (Twt) was taken as 100%.
days in the presence of2% DMSO. Expression of the transfected
gene was assessed by an S 1 -nuclease protection assay using
end-labelled DNA probes (Fig. 4).
Functional analysis of TATA box mutants; TBP
binding is not rate limiting in transcription initiation
Mutants that prevent the binding of SpI (mT1), GATA-1 (mT2)
and YY1 (mT3) near the TATA box (Fig. 2B), still gave full
transcriptional activation (Fig. 4A, lanes mTl, mT2 and mT3).
The only mutants in this region that decreased transcription (Fig.
4B,C) were those which markedly reduced the binding of TBP,
namely mT5, mT7 and mTO0 (Fig. 3) of which mT5 (-29 A to C)
is a natural 0-thalassaemia mutation (37). Interestingly, three of
the mutants that showed a reduced binding forTBP namely mT3,
mT6 and mT9 (Fig. 3), did not result in decreased transcription
(Fig. 4A-C). Only when the ability to bind TBP is reduced still
further (mT5, mT7 and mT1O), does this result in decreased
expression (Table 2), in agreement with the lower levels of
i-globin RNA found in patients with the mT5 mutation (37). As
the [-H2K hybrid mRNA is stable, the steady state cytoplasmic
levels of this sequence are directly proportional to rates of
transcription. Therefore, these data indicate that maximum
initiation oftranscription can be achieved once a certain threshold
in the efficiency of TF IID binding to the promoter is reached.
This also clearly suggests that the ability of the TATA box to bind
TF IID is not limiting in the rate of initiation of transcription.
expression cassette as a -H2 hybrid gene (22). Table 2 shows a
list of the mutants built into this expression system. These
constructs were then introduced into MEL cells by electropora-
tion and two or three large pools of stable transfected, G418
resistant clones selected (28). RNA was then isolated from cells
that had been induced to undergo erythroid differentiation for 4
Functional analysis of Cap site mutants
Three mutants ofthe cap site region were also tested. MutantmCI
affects only the binding ofCl while mC2 abolishes binding ofCl
and GATA-1 (see DNA contact sites, Table 1). Neither of these
caused a decrease in transcription (Fig. 4E, lanes mCI and mC2).
In addition, a natural I+-thalassaemia mutant (mC3) which
consists of a change of the initiating A to a C residue (38), was
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Table 2. Efficiency of TBP binding and expression levels from the TATA
box and cap site mutants of the human f-globin promoter in MEL cells
.... .... ....
AGAGcCATCTAG ACA GCt~_ L431.......... TI_
-30 -20 -10 +1
Construct Mutation TBP Correct Otherbinding start starts
WT 100 100
mTl Spl 100 100
mT2 GATA- 1 120 100
mT3 Wi 53 100
mT5 TBP 13.3 38.5
mT6 TBP 32 100
mT7 TBP <4 14
mT8 Mouse TATA 150 100
mT9 Chicken TATA 52 100
mTl 0 GATA-1 +/TBP- 4.2 28 8.4
mCl C1 100
mC2 GATA-1 100
mC3 +1A)-C 64.5 40
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The top panel shows a schematic representation of the position of the different
proteins binding to the human 3-globin promoter sequence. The middle panel
shows the quantitation of the efficiency ofTBP binding to the different mutant
oligonucleotides (see Table 1 and Fig. 3) and the amount of RNA transcribed
from the +1 or downstream positions of the constructs containing these muta-
tions (Fig. 4). The wild type (WT) promoteris taken as a 100% standard forboth
TBP binding-and expression levels ofcorrectly initiated transcripts. The bottom
panel shows a graphic illustration ofthe amount ofRNA transcribed from these
constructs versus the amount of TBP binding.
also tested. This mutation also reduces the binding of the C1, but
notC2A and GATA- proteins. It results in a small decrease ofthe
total amount of transcription, of which a large part is initiated
aberrantly, in particular, between 5 and 8 nucleotides upstream of
the wild type cap site (Fig. 4E, lanes mC3). We conclude that the
reduction in the level of transcription observed with the mC3, is
largely due to the fact that the initiation nucleotide A has been
changed, leading to aberrant starts, rather than to the fact that C1
binding has been affected. The reduced level ofRNA correlates
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Figure 4. Expression analysis ofTATA box and cap site mutants in MEL cells.
The TATA box and cap site mutants for the various factors listed in Table 1 were
built into the ,LCR expression cassette and used to generate stable transfected,
G418 resistant pools ofMEL cells (see Materials and Methods). Total RNAwas
isolated from the large pools of clones that were produced after they had been
induced to undergo 4 days of erythroid differentiation in the presence of 2%
DMSO. Samples (2 ig) were simultaneously assayed for the f-H2 transgene
and the endogenous 3-maj globin sequences by SI-nuclease protection using
end-labelled DNA probes which detect the 5' end of the mRNAs. The
Sl-nuclease protected fragment for the 1-H2 mRNA is 85 nucleotides and that
for ,B-maj 96 nucleotides. Homologous probes for the TATA and cap mutants
were employed. Panel D is a longer exposure of panel C and shows the minor
bands corresponding to initiation events downstream of the normal Cap site.
WT refers to the result obtained with the wild type promoter. mTl-mT10 refer
to the TATA box mutants and mCl-mC3 to the cap mutants. The results were
quantified by phosphorimage analysis correcting for variation in eryturoid
induction levels by using fS-maj globin as an internal standard. The level
obtained with the wild type promoter was taken as 100% expression (see Table
2). Different specific activity probes were used on different gels. Only a small
part of the gels is shown for space reasons.
well with the observed very mild thalassaemia which arises from
this mutation in human subjects (38).
Testing specialized TATA elements
Our observation that GATA-1 binding at the human P-globin
TATA box does not appear to be functionally significant, is at
variance with the results obtained with this same region from the
chicken gene (25). This could possibly be explained by the fact
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Figure 5. Expression analysis ofTATA box mutants in murine L-cells. Selected TATA box mutants (see Table 1) were stably transfected into mouse fibroblast L-cells
by lipofection (see Materials and Methods). Total RNA from the three independent pools ofclones that were generated was then analysed by an SI -nuclease protection
assay, as described in Figure 4. Assays probed for the ,B-H2 sequences (upper panel) contained 20 ig RNA per reaction. Samples (2 gg) were also assayed for IS-actin
mRNA as a loading control. The 1-H2 probe gives the same ,B-H2 Sl-protected product as in Figure 4. The 3-actin probe gives a 100 nucleotide SI-protected product.
RNA from untransfected L-cells (L) and 13-H2 transfected MEL (M) acted as negative and positive controls, respectively.
that GATA-1 binds downstream of the TATA box in the human
f-globin promoter rather than at the TATA box as is the case in
the chicken ,3-globin promoter. The sequence of the chicken
0-globin TATA box is AGATAAAA, which allows it to bind
GATA-1 strongly as opposed to the corresponding human
element (ACATAAAA). Since the function of GATA-1 in the
chicken f-globin study was assessed by in vitro transcription and
transient transfection assays, we decided to test whether its
proposed specialized role at the TATA box could be extended to
chromatin as part of our LCR based expression system. We
therefore built TATA elements within the human j-globin
promoter with varying affinities forTF IID and GATA-l (Figs 2B
and 3 and Table 2). The TATA box regions of the mouse (mT8),
human (wt) and chicken (mT9) ,-globin genes have a different
affinity for TBP (Fig. 3), which are 150, 100 and 50%,
respectively, (Table 1) using the human sequence as the standard.
In contrast, the chicken sequence has a much higher affmity for
GATA-1 as expected (Fig. 2B, Table 2). In addition, we built a
mutant TATA element, mTl0 (AGATAGCC), which binds
GATA-1 (Fig. 2B, lane T10) as strongly as the chicken element,
but which has minimal binding ofTBP (Fig. 3). The severe TATA
mutant mT7, acted as a control which does not bind TBP (Fig. 3,
Table 2), but which retained GATA- 1 binding at -12 like the other
constructs in this series (Fig. 2B).
Expression ofthese mutants inMEL cells revealed that the wild
type human P-globin TATA box (Fig. 4C, lane WT, Table 2),
directed initiation of transcription with equal efficiency as that
from the mouse (Fig. 4C, lanes mT8) or chicken (Fig. 4C, lanes
mT9) genes. Thus, the higher affinity for GATA-1, seen with the
chickenTATA box does not result in any physiological effect. The
only difference that could be discerned between the mouse or
human and chicken elements was the appearance of aberrant
transcripts initiated downstream of the natural cap site (Fig. 4D).
Some of these appear to be GATA-1 stimulated transcripts and
some were the result of weak TF IID binding as shown by the
different starts inmT7 andmT0 (Fig. 4D). The mTl0 mutant has
the same GATA-I binding capacity as the chicken TATA box (mT9),
but very low affinity for TBP (Fig. 3, Table 2). Interestingly, the
mTlO (GATA-1) promoter produced 2-fold more correctly
initiated transcripts than the severe TATA mutant mT7 (Fig. 4C,
Table 2). In order to confirm that this difference was due to the
observed higher affinity for TBP by mT1O than that by mT7 (Fig.
3), we carried out transfections in mouse fibroblast L-cells which
are devoid of GATA-1. Stable transfected pools of 200-300
clones of L-cells carrying the same WT, mT7, mT8, mT9 and
mT1O promoter constructs as used in MEL cells, were produced.
Expression of the transgene was assessed by S I-nuclease
protection as before (Fig. 5). The results show that all of the
promoters give only the normal site oftranscription initiation; that
is, the aberrant transcription starts seen with the mT9 and mT1O
promoters in MEL cells, are absent in L-cells. This supports the
notion that these aberrant initiated products in MEL cells are due to
GATA-1 binding at the TATA box region of these constructs. This
suggests that GATA-l and TF 11D binding at the TATA box do not
co-operate in the initiation of trnscription, but that GATA competes
with normal TATA box directed initiation at +1. However, attempts
to show this directly by co-transfection ofGATA expression vectors
in L-cells failed because we were unable to obtain levels ofGATA-l
comparable to those seen in MEL cells (data not shown).
It is also important to note that the relative differences in
transcription efficiency observed in the L-cells are different to
those observed in MEL cells. For example, the WT/mT7 ratio is
higher in MEL cells (7-fold) than in L cells (3- to 4-fold),
suggesting that conclusions on tissue specific promoters should
preferably be based on results obtained in homologous systems.
Finally, relatively high levels of correctly initiated transcripts
observed with the TATA box mutants mT7 (14%) andmTlO (28%)
(Fig. 4C,D; Table 2) suggests that either upstream promoter factors
or an Ir element (or both) are involved in placing TF IID at the
TATA box region. Since we did not detect binding ofthe previously
characterized hIr binding protein TF I-I (35) to the transcriptional
start site, we decided to reassess if the factor Cl (Fig. 1) could
function in this capacity. The analysis ofdouble mutants consisting
of the mT7 or mT1O TATA box and mCl cap site combinations
(Table 1), resulted in a further reduction in the level of correctly
initiated transcripts relative to that obtained with the single mT7
and mTlO promoters (data not shown). This suggests that Ci
protein can function as an Inr protein in the context ofa weakTATA
element but whose physiological significance at present remains
unclear.
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DISCUSSION
In this study we have exploited the human [B globin LCR expression
system to study the factors involved in the initiation of tansciption
from the f-globin gene. This system allows quantitative functional
expression assays to be perfonned at physiological levels in vivo in
contrast to reports on this topic which predominantdy use in vitro
transcription assays with nuclear extacts or transient transfection
experiments. We have previously demonstrated iat the j3LCR can
fully activate erthroid specific btanscription through the proximal
promoter (-90, CACC and -75, CCAAT) elements of the f-globin
gene (22). In this study we investigated factors binding over the
TATA box and Cap site regions.
Protein-DNA binding studies in vitro using nuclear extracts
from erythroid (MEL, K562) and non-erythroid (HeLa) cells
showed that in addition to TBP, three other factors were found to
bind around the TATA box of the human 0-globin gene (Table 2).
These were the erythroid factor GATA-1, the ubiquitous tran-
scription factor Spi, a transcriptional activator (39) and a
YY1-like protein which can function both as a transcriptional
inhibitor as well as an initiator protein (32,33). For reasons that
are presently not clear, we find no evidence for the binding
activity reported by Stuve and Myers (24). Expression studies in
MEL cells with LCR driven promoters carrying mutations which
abolish the binding of Spi, YYl or GATA- 1, resulted in wild type
levels of transcription (Fig. 4A and B; Table 2), indicating that
these proteins have no significant role at the TATA box in vivo.
The various TATA box mutants tested in this study allowed us
to address the question of TBP binding efficiency in regulating
initiation of transcription. Electrophoretic mobility shift assays
with recombinant TBP (Fig. 3), indicated the following order of
binding efficiency for this factor by the TATA elements tested:
mouse (mT8), 150%; human (wt), 100%; chicken (mT9) and
mT3, 50%; mT6, 30%; mT5, 13%; mT1O, 4%; mT7, <4% using
human (wt) as a 100% reference. Despite the fact that the binding
ofTBP to the mT9, mT3 and mT6 mutants (Table 2) is between
50 and 30% of the normal human sequence, equal rates of
transcription initiation are observed in vivo (Fig. 4A and B).
Again, in the case of the T5 (-28 A to C) mutant which binds TBP
at 13% of wild type, transcription is still 30% compared to wild
type. Interestingly, the mT5 level of transcription is in agreement
with that observed in the 0-thalassaemia patients which carry this
mutation (37), emphasizing that our model system mimics the in
vivo situation. However, it is known that TF IID partially purified
from HeLa cells produces a DNaseI footprint over the adenovirus
major late (AdML) promoter which extends from the TATA box
to past the cap site (2,40). This is in marked contrast to
recombinant TBP which only footprints the TATA box element
(41-43). The extended footprint given by TF UD is now known
to be due to the TAF]g150 component of this complex (44). We
therefore also attempted to correlate in vitro TF IID rather than
TBP binding with transcriptional efficiency in vivo by isolating
an enriched TF IID fraction from MEL cells and compared it to
a highly enriched TF IID containing fraction from human (HeLa)
cells (a generous gift from P. Verrijzer and R. Tjian). However,
none ofthese fractions (MEL or HeLa) gave EMSAs which could
be quantitated with either the wild type or mutant oligonucleo-
tides used in the TBP binding experiments. Nevertheless, our
results indicate that the efficiency of TBP (and probably TF HID)
binding at the TATA box is not the rate limiting step in
maximum initiation of transcription will occur. This threshold
value would appear to be quite low and of the order of 15-30%
of a strong binding site like the human TATA box which is
comparable to that from the AdML promoter (36).
The TATA box mutants mT7 and mTlO have only a weak TBP
binding activity (Fig. 3) which is much lower than the inherent
TBP binding capacity at the -30 region ofsome native TATA-less
promoters (45). However, these two mutants still gave significant
levels of correctly initiated transcripts (Fig. 4C; Table 2). This
may be due to number of different reasons. First, since TAF1I 150
can bind to DNA independently ofTBP (44), this may reflect the
residual in vivo binding capacity of TF IID to these TATA box
mutants due to this TAF component of the complex. However,
this is unlikely to completely account for the observed levels of
expression given that TATA box mutants ofthe Ad2 E1B gene are
unable to compete the binding of a purified HeLa cell TF IID
fraction to the wild type element (5). This indicates that the
binding of TAFII150 to DNA is weak compared to the TF IID
complex as a whole. Alternatively, the binding of TF IID to the
mT7 and mT10 mutants may be mediated by an Inr function or
by factors associated with upstream promoter elements such as
the -200 GATA-1, -85 CACC or -75 CCAAT regions which
could position TBP as part ofTFUD at the natural TATA position
through some tethering capacity, either by interacting directly
with TF IID or through an intermediary, co-activator protein or
TAF (46). However, the observation that most of the transcripts
have aberrant downstream start sites (Fig. 4D) would indicate that
the 'tethering' capacity of these upstream factors is generally a
loose one, resulting in the positioning ofTFUD and subsequently
the initiation complex as a whole, over an extended region rather
than a single site. This resembles the situation for transcripts from
many TATA-less promoters which usually have a cluster of start
sites and no demonstrated Ir function.
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